Boiron Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Boiron wird ein jährliches Gewinn- und Umsatzwachstum von 13.1% bzw. 4.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.6% betragen.

Wichtige Informationen

13.1%

Wachstumsrate der Gewinne

12.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	16.1%
Wachstumsrate der Einnahmen	4.3%
Zukünftige Eigenkapitalrendite	8.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Does The Market Have A Low Tolerance For Boiron SA's (EPA:BOI) Mixed Fundamentals?

Feb 02

Should You Buy Boiron SA (EPA:BOI) For Its Dividend?

Jan 19

Does Boiron's (EPA:BOI) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 27

What Kind Of Shareholders Hold The Majority In Boiron SA's (EPA:BOI) Shares?

Dec 14

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:BOI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	537	46	55	78	2
12/31/2024	508	38	49	69	1
12/31/2023	493	36	27	45	N/A
9/30/2023	505	42	23	40	N/A
6/30/2023	517	48	18	34	N/A
3/31/2023	526	46	29	46	N/A
12/31/2022	534	45	40	59	N/A
9/30/2022	528	48	44	64	N/A
6/30/2022	522	51	48	69	N/A
3/31/2022	489	40	31	51	N/A
12/31/2021	455	29	13	33	N/A
9/30/2021	453	23	13	34	N/A
6/30/2021	450	18	14	34	N/A
3/31/2021	482	22	31	51	N/A
12/31/2020	514	26	48	68	N/A
9/30/2020	534	33	52	76	N/A
6/30/2020	554	40	57	84	N/A
3/31/2020	556	40	35	67	N/A
12/31/2019	557	41	13	51	N/A
9/30/2019	569	38	19	59	N/A
6/30/2019	580	35	25	68	N/A
3/31/2019	592	46	31	76	N/A
12/31/2018	604	57	37	84	N/A
9/30/2018	609	66	43	92	N/A
6/30/2018	613	75	49	99	N/A
3/31/2018	615	77	50	102	N/A
12/31/2017	618	78	51	105	N/A
9/30/2017	616	77	N/A	104	N/A
6/30/2017	615	76	N/A	103	N/A
3/31/2017	615	77	N/A	106	N/A
12/31/2016	614	78	N/A	110	N/A
9/30/2016	616	78	N/A	103	N/A
6/30/2016	617	79	N/A	95	N/A
3/31/2016	612	76	N/A	99	N/A
12/31/2015	608	74	N/A	103	N/A
9/30/2015	616	83	N/A	114	N/A
6/30/2015	624	91	N/A	125	N/A
3/31/2015	617	90	N/A	111	N/A
12/31/2014	610	89	N/A	96	N/A
9/30/2014	607	83	N/A	91	N/A
6/30/2014	604	76	N/A	86	N/A
3/31/2014	611	79	N/A	96	N/A
12/31/2013	618	82	N/A	107	N/A
9/30/2013	609	74	N/A	110	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BOIDas prognostizierte Gewinnwachstum (13.1% pro Jahr) liegt über der Sparquote (1.1%).

Ertrag vs. Markt: BOIDie Erträge des Unternehmens (13.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (11% pro Jahr).

Hohe Wachstumserträge: BOIDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: BOIDie Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt French (5.8% pro Jahr).

Hohe Wachstumseinnahmen: BOIDie Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BOIDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.6%).

Boiron Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 21%

Price target decreased by 7.3% to €43.93

Price target decreased by 14% to €44.55

Price target increased to €52.67

Price target increased to €47.33

Consensus forecasts updated

Recent updates

Upcoming dividend of €1.35 per share

First half dividend of €1.35 announced

Consensus EPS estimates fall by 21%

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

Price target decreased by 7.3% to €43.93

Investor sentiment deteriorates as stock falls 25%

Upcoming dividend of €10.36 per share at 2.0% yield

First half 2023 earnings released: EPS: €0.89 (vs €0.72 in 1H 2022)

Price target decreased by 14% to €44.55

New minor risk - Share price stability

Investor sentiment improves as stock rises 30%

Upcoming dividend of €1.10 per share at 2.8% yield

Full year 2022 earnings released

Calculating The Intrinsic Value Of Boiron SA (EPA:BOI)

First half 2022 earnings released: EPS: €0.72 (vs €0.54 loss in 1H 2021)

Price target increased to €52.67

Upcoming dividend of €0.95 per share

Boiron (EPA:BOI) Has Re-Affirmed Its Dividend Of €0.95

Full year 2021 earnings: Revenues in line with analyst expectations

Price target increased to €47.33

Boiron SA (ENXTPA:BOI) signed an agreement to acquire 70% stake in Abbi.

Consensus forecasts updated

Estimating The Intrinsic Value Of Boiron SA (EPA:BOI)

Price target increased to €45.67

Price target increased to €43.67

First half 2021 earnings released: €0.54 loss per share (vs €0.056 loss in 1H 2020)

Price target increased to €42.33

Upcoming dividend of €0.95 per share

Is Boiron SA's (EPA:BOI) 2.3% Dividend Worth Your Time?

Consensus EPS estimates fall to €0.96

Boiron (EPA:BOI) Has A Pretty Healthy Balance Sheet

Full year 2020 earnings released: EPS €1.50 (vs €2.32 in FY 2019)

Analysts lower EPS estimates to €1.71

Reflecting on Boiron's (EPA:BOI) Share Price Returns Over The Last Three Years

New 90-day low: €34.00

Boiron SA to Report Fiscal Year 2020 Results on Mar 10, 2021

A Look At The Intrinsic Value Of Boiron SA (EPA:BOI)

Does The Market Have A Low Tolerance For Boiron SA's (EPA:BOI) Mixed Fundamentals?

French Agency for the Safety of Medicines and Health Products Selects Emmac Life Sciences Group in Partnership with Boiron as the Suppliers for the Forthcoming French Medical Cannabis Trial

Analysts lower EPS estimates to €0.76

New 90-day low: €36.10

Should You Buy Boiron SA (EPA:BOI) For Its Dividend?

Does Boiron's (EPA:BOI) Statutory Profit Adequately Reflect Its Underlying Profit?

What Kind Of Shareholders Hold The Majority In Boiron SA's (EPA:BOI) Shares?

Analysts update estimates

New 90-day high: €40.80

Analysts update estimates

Price target raised to €40.07

First half earnings released

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken